Increased HbA1c Identifies Rapid Kidney Function Deterioration in Diabetics
By LabMedica International staff writers Posted on 13 Nov 2019 |

Image: Diabetes and higher HbA1c levels are independently associated with adverse renal outcomes in inpatients following multiple hospital admissions (Photo courtesy of Anitha Anchan).
Among adults with multiple hospital admissions, those with type 2 diabetes were more likely to have worsening renal function compared with those without diabetes. The association between glycemic status prior to the first hospital presentation with developing adverse renal outcomes overtime in patients with multiple hospital re-admissions has been assessed.
While poor glycemic control defined by higher HbA1c levels is associated with worse renal outcomes, the presence of diabetes independent of glycemic status is also associated with high risk of relatively rapid deterioration in renal function. Therefore, all patients with diabetes, regardless of their glycemic control, are a logical target for structured preventive interventions.
A team of scientists from the University of Melbourne (Melbourne, Australia) conducted a prospective observational cohort study with 4,126 adults aged at least 54 years who made two or more visits to Austin Hospital (Heidelberg, Australia) from 2013 to 2016 (median age, approximately 77 years; 41% women). Participants had estimated glomerular filtration rates of more than 30 mL/min/1.73 m2 and “no prior history of renal replacement therapy” before study onset. The team analyzed data on HbA1c and eGFR from 465 days of median follow-up time.
Diabetes was diagnosed in 26% of the population and the scientists noted that stage 4 chronic kidney disease developed in 19% of those with diabetes and 13% of those without diabetes. Among adults with multiple hospital admissions, those with type 2 diabetes were more likely to have worsening renal function compared with those without diabetes.
An eGFR decrease of more than 50% was more likely to occur for participants with diabetes versus without diabetes. The team also noted a higher predicted adjusted probability for those with diabetes and an eGFR of at least 45 mL/min/1.73 m2 before study onset. A “rapid decline in renal function,” which was characterized by an annual decrease in eGFR of more than 5 mL/min/1.73 m2, was more likely to occur for participants with versus without diabetes particularly between the first and second year of follow-up.
Ending the study at an eGFR of 30 mL/min/1.73 m2 was more likely for participants with diabetes compared with those without diabetes. The scientists noted that HbA1c at study onset did not affect the likelihood of ending at an eGFR of 30 mL/min/1.73 m2, but that it became 7% more likely that a 50% eGFR decrease would occur and 11% more likely that a “rapid decline” would occur with each HbA1c increase of 1% at baseline.
Niloufar Torkamani, MD, PhD, FRACP, an endocrinology/general medicine physician and lead author of the study, said, “We found that the presence of diabetes and higher HbA1c levels were strongly and independently associated with adverse renal outcomes at follow-up. Such patients are at high risk of relatively rapid deterioration in renal function and are a logical target for structured preventive interventions.” The study was published on October 22, 2019 in the Journal of Diabetes and its Complications.
Related Links:
University of Melbourne
Austin Hospital
While poor glycemic control defined by higher HbA1c levels is associated with worse renal outcomes, the presence of diabetes independent of glycemic status is also associated with high risk of relatively rapid deterioration in renal function. Therefore, all patients with diabetes, regardless of their glycemic control, are a logical target for structured preventive interventions.
A team of scientists from the University of Melbourne (Melbourne, Australia) conducted a prospective observational cohort study with 4,126 adults aged at least 54 years who made two or more visits to Austin Hospital (Heidelberg, Australia) from 2013 to 2016 (median age, approximately 77 years; 41% women). Participants had estimated glomerular filtration rates of more than 30 mL/min/1.73 m2 and “no prior history of renal replacement therapy” before study onset. The team analyzed data on HbA1c and eGFR from 465 days of median follow-up time.
Diabetes was diagnosed in 26% of the population and the scientists noted that stage 4 chronic kidney disease developed in 19% of those with diabetes and 13% of those without diabetes. Among adults with multiple hospital admissions, those with type 2 diabetes were more likely to have worsening renal function compared with those without diabetes.
An eGFR decrease of more than 50% was more likely to occur for participants with diabetes versus without diabetes. The team also noted a higher predicted adjusted probability for those with diabetes and an eGFR of at least 45 mL/min/1.73 m2 before study onset. A “rapid decline in renal function,” which was characterized by an annual decrease in eGFR of more than 5 mL/min/1.73 m2, was more likely to occur for participants with versus without diabetes particularly between the first and second year of follow-up.
Ending the study at an eGFR of 30 mL/min/1.73 m2 was more likely for participants with diabetes compared with those without diabetes. The scientists noted that HbA1c at study onset did not affect the likelihood of ending at an eGFR of 30 mL/min/1.73 m2, but that it became 7% more likely that a 50% eGFR decrease would occur and 11% more likely that a “rapid decline” would occur with each HbA1c increase of 1% at baseline.
Niloufar Torkamani, MD, PhD, FRACP, an endocrinology/general medicine physician and lead author of the study, said, “We found that the presence of diabetes and higher HbA1c levels were strongly and independently associated with adverse renal outcomes at follow-up. Such patients are at high risk of relatively rapid deterioration in renal function and are a logical target for structured preventive interventions.” The study was published on October 22, 2019 in the Journal of Diabetes and its Complications.
Related Links:
University of Melbourne
Austin Hospital
Latest Clinical Chem. News
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
Channels
Molecular Diagnostics
view channel
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more